Special Issue "Challenging Aspects of Botulinum Toxin Therapy"
Deadline for manuscript submissions: closed (19 October 2021).
Interests: multiple sclerosis; neuromyelitis spectrum disorders; optical coherence tomography; visual evoked potentials; botulinum neurotoxin therapy; general neurology
This issue is aimed at describing the history of botulinum neurotoxin (BoNT) therapy and the development of the broad spectrum of neurological and non-neurological indications. It also deals with the continuous purification attempts to improve biological function and to reduce immunoresistance. It emphasizes that BoNT-therapy is highly effective, but is not a causal therapy. For a good outcome tissue, muscle and dose selection have to be optimized and different guidance techniques should be used. Knowledge of the course of disease before and after BoNT-therapy is important. This underlines the relevance of documentation of injection sites, dose per site and the use of clinical scores for carefully monitoring BoNT-therapy carefully and the assessment of patients´ experience of improvement of quality of life. The side effects of BoNT-therapy are mild and sometimes overestimated. Development of an immunoresistance can be a limiting factor of BoNT-therapy. Different clinical and laboratory tests have been developed for the early detection of a partial secondary treatment failure. Possible strategies how to proceed when a secondary treatment failure has become clinically manifest should also be included into this issue.
This issue would cover the mentioned above aspects in general with focus on following points:
- Botulinum neurotoxin (BoNT) therapy in clinical neurology
- Gathering real world evidence for neurological BoNT therapy
- Established and emerging indications
- Personal experience with tips and tricks in neurological BoNT therapy
- Issues related to BoNT/A therapy and neutralizing antibodies
- Laboratory and clinical tests for detecting antibody formation
- Special cases in Botulinum Toxin Therapy (case reports and literature reviews) (cases without BoNT indication approval – therapy resistant cases – unusual cases -…)
- BoNT therapy challenges in the time of Covid-19 pandemic and lockdown
Prof. Dr. Harald Hefter
Prof. Dr. Philipp Albrecht
Dr. Sara Samadzadeh
Dr. John-Ih Lee
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- botulinum neurotoxin (BoNT)
- botulinum neurotoxin type A(BoNT/A)
- neutralizing antibodies
- primary and secondary treatment failure
- complex protein-free BoNT/A
- complex protein containing BoNT/A
- therapy switching